Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Cancer Vaccines01:30

Cancer Vaccines

383
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Rethinking ovarian cancer III: the past decade and future directions.

Nature reviews. Cancer·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Investigating changes in serum metabolome and urinary endocrine disrupting chemicals in cats with hyperthyroidism.

Veterinary research communications·2026
Same author

Top 10 research priorities for adolescent and young adult cancer in Canada: a James Lind Alliance priority setting partnership.

BMJ open·2026
Same author

Adenosine drives suppression of CD16low NK cell responses against HGSC via NKG2A:hLA-E interactions.

Journal of leukocyte biology·2026
Same author

An Environmental Scan of Services for Adolescents and Young Adults Diagnosed with Cancer Across Canadian Pediatric and Adult Tertiary Care Centres.

Current oncology (Toronto, Ont.)·2026
Same journal

Reply to the discussion of "Efficacy of lactoferrin supplementation in pediatric infections: a systematic review and metanalysis".

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same journal

Discussion of "Efficacy of lactoferrin supplementation in pediatric infections: a systematic review and meta-analysis".

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same journal

Does the beta subunit of mitochondrial trifunctional protein modulate monolysocardiolipin acylation to cardiolipin?

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same journal

Distinct effects of disease-associated mutations in the proximal C-linker on negatively cooperative binding of cyclic nucleotides to the human HCN4 channel.

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same journal

PPP2R2B targets the JAK2-STAT3 signaling pathway to regulate ferroptosis in breast cancer cells.

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same journal

Suppression of CBP/p300 induces growth inhibition and autophagy of hepatocellular carcinoma cells through regulation of EPHA2 by its super-enhancer acetylation.

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
查看所有相关文章

相关实验视频

Updated: Jul 12, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

78

2022年癌症免疫治疗的BioCanRx峰会 会议记录

Stacey N Lee1,2,3,4, Victoria Hoskin2,5, Céline M Laumont2,6,7

  • 1BioCanRx HQP Summit4CI Working Group, BioCanRx, Ottawa, ON, Canada.

Biochemistry and cell biology = Biochimie et biologie cellulaire
|October 23, 2023
PubMed
概括
此摘要是机器生成的。

癌症免疫治疗的BioCanRx峰会召集了专家,讨论癌症生物治疗的进展. 关键话题包括细胞疗法,工程,试验和微生物组,强调患者参与.

关键词:
采用细胞疗法采用细胞疗法癌症免疫疗法免疫疗法免疫瘤学 免疫瘤学免疫疗法 免疫疗法会议 研讨会 研讨会患者合作伙伴是患者的合作伙伴.

更多相关视频

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

相关实验视频

Last Updated: Jul 12, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

78
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 生物技术是生物技术.

背景情况:

  • 癌症免疫治疗的BioCanRx峰会标志着疫情后重返面对面的会议.
  • 该活动聚集了各种利益相关者,包括患者,研究人员,临床医生和行业专业人士.

研究的目的:

  • 审查2022年BioCanRx癌症免疫治疗峰会的主要讨论和成果.
  • 突出加拿大癌症生物治疗的进展和未来方向.

主要方法:

  • 这次会议包括三个全体会议,主题演讲者,辩论,小组讨论和海报会议.
  • 通过诸如BioCanRx学习研究所等举措,患者的观点得到了整合.

主要成果:

  • 讨论涵盖了细胞疗法,细胞工程,临床试验和癌症微生物组的现状.
  • 该活动促进了癌症免疫疗法利益相关者之间的知识交流和联网.

结论:

  • 峰会成功地将关键参与者聚集在一起,以推进癌症免疫治疗研究和开发.
  • 整合患者的声音对于癌症生物治疗研究的未来至关重要.